Fibrinogen
Fibrinogen alpha/beta chain family | |||||||||
---|---|---|---|---|---|---|---|---|---|
|
Fibrinogen alpha C domain | |||||||||
---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||
Symbol | Fibrinogen_aC | ||||||||
Pfam | PF12160 | ||||||||
InterPro | IPR021996 | ||||||||
|
Identifiers | |||||||||
---|---|---|---|---|---|---|---|---|---|
Symbol | Fibrinogen_C | ||||||||
SCOP2 | 1fza / SCOPe / SUPFAM | ||||||||
|
Fibrinogen (factor I) is a
Reduced and/or dysfunctional fibrinogens occur in various congenital and acquired human fibrinogen-related disorders. These disorders represent a group of rare conditions in which individuals may present with severe episodes of pathological bleeding and thrombosis; these conditions are treated by supplementing blood fibrinogen levels and inhibiting blood clotting, respectively.[4][5] These disorders may also be the cause of certain liver and kidney diseases.[1]
Fibrinogen is a "positive" acute-phase protein, i.e. its blood levels rise in response to systemic inflammation, tissue injury, and certain other events. It is also elevated in various cancers. Elevated levels of fibrinogen in inflammation as well as cancer and other conditions have been suggested to be the cause of thrombosis and vascular injury that accompanies these conditions.[6][7]
Genes
Fibrinogen is made and secreted into the blood primarily by liver
|
|
|
Structure
The Aα, Bβ, and γ chains are
The fibrinogen molecule circulates as a soluble
Blood clot formation
During blood clotting,
Fibrin participates in limiting blood clot formation and degrading formed blood clots by at least two important mechanisms. First, it possesses three low affinity binding sites (two in fibrin's E domain; one in its D domain) for thrombin; this binding sequesters thrombin from attacking fibrinogen.
Fibrinogen disorders
Several disorders in the quantity and/or quality of fibrinogen cause pathological bleeding, pathological blood clotting, and/or the deposition of fibrinogen in the liver, kidneys, and other tissues.
Congenital afibrinogenemia
Congenital afibrinogenemia is a rare and generally
Congenital hypofibrinogenemia
Congenital hypofibrinogenemia is a rare inherited disorder in which blood may not clot normally due to reduced levels of fibrinogen (plasma fibrinogen typically <150 but >50 mg/dl). The disorder reflects a disruptive mutation in only one of the two parental FGA, FGB, or FBG genes and has a low degree of genetic penetrance, i.e. only some family members with the defective gene ever exhibit symptoms. Symptoms of the disorder, which more often occurs in individuals with lower plasma fibrinogen levels, include episodic bleeding and thrombosis that typically begin in late childhood or adulthood.[4]
Fibrinogen storage disease
Fibringogen storage disease is an extremely rare disorder. It is a form of congenital hypofibrinogenemia in which certain specific hereditary mutations in one copy of the FGG gene causes its fibrinogen product to accumulate in, and damage, liver cells. The disorder has not reported with FGA or FGB mutations. Symptoms of these FGG mutations have a low level of penetrance. The plasma fibrinogen levels (generally <150 but >50 mg/dl) detected in this disorder reflect the fibrinogen made by the normal gene. Fibrinogen storage disease may lead to abnormal bleeding and thrombosis but is distinguished by also sometimes leading to liver cirrhosis.[19]
Congenital dysfibrinogenemia
Congenital dysfibrinogenemia is a rare
Hereditary fibrinogen Aα-Chain amyloidosis
Hereditary fibrinogen Aα-Chain amyloidosis is an autosomal dominant extremely rare inherited disorder caused by a mutation in one of the two copies of the FGA gene. It is a form of congenital dysfibrinogenemia in which certain mutations lead to the production of an abnormal fibrinogen that circulates in the blood while gradually accumulating in the kidney. This accumulation leads over time to one form of familial renal amyloidosis. Plasma fibrinogen levels are similar to that seen in other forms of congenital dysfibrinogenemia. Fibrinogen Aα-Chain amyloidosis has not associated with abnormal bleeding or thrombosis.[21]
Acquired dysfibrinogenemia
Acquired dysfibrinogenemia is a rare disorder in which circulating fibrinogen is composed at least in part of a dysfunctional fibrinogen due to various acquired diseases. One well-studied cause of the disorder is severe
Congenital hypodysfibrinogenemia
Congenital hypodysfibrinogenemia is a rare inherited disorder in which low levels (i.e. <150 mg/dl) of immunologically detected plasma fibrinogen are composed at least in part of a dysfunctional fibrinogen. The disorder reflects mutations typically in both inherited fibrinogen genes, one of which produces a dysfunctional fibrinogen, while the other produces low amounts of fibrinogen. The disorder, while having reduced penetrance, is usually more severe than congenital dysfibrinogenemia, but like the latter disorder, causes pathological episodes of bleeding and/or blood clotting.[22]
Cryofibrinogenemia
Acquired hypofibrinogenemia
Acquired hypofibrinogenemia is a deficiency in circulating fibrinogen due to excessive consumption that may occur as a result of
Laboratory tests
Clinical analyses of the fibrinogen disorders typically measure blood clotting using the following successive steps:
- Blood clotting is measured using standard tests, e.g. prothrombin time, partial thromboplastin time, thrombin time, and/or reptilase time. Low fibrinogen levels and dysfunctional fibrinogens usually prolong these times, whereas the lack of fibrinogen (i.e. afibrinogenemia) renders these times infinitely prolonged.
- Fibrinogen levels are measured in the prothrombin based methods.[31]Normal levels being about 1.5-3 g/L, depending on the method used. These levels are normal in dysfibrinogenemia (i.e. 1.5-3 g/L), decreased in hypofibrinogenemia and hypodysfibrinogenemia (i.e. <1.5 g/L), and absent (i.e. <0.02 g/L) in afibrinogenemia.
- Functional levels of fibrinogen are measured on plasma induced to clot. The levels of clotted fibrinogen in this test should be decreased in hypofibrinogenemia, hypodysfibrinogenemia, and dysfibrinogenemia and undetectable in afibrinogenemia.
- Functional fibrinogen/antigenic fibrinogen levels are <0.7 g/L in hypofibrinogenemia, hypodysfibrinogenemia, and dysfibrogenemia, and not applicable in afibrinogenemia.
- Fibrinogen analysis can also be tested on whole-blood samples by thromboelastometry. This analysis investigates the interaction of coagulation factors, their inhibitors, anticoagulant drugs, and blood cells (specifically, platelets), during clotting and subsequent fibrinolysis as it occurs in whole blood. The test provides information on hemostatic efficacy and maximum clot firmness to give additional information on fibrin-platelet interactions and the rate of fibrinolysis (see Thromboelastometry).
- Scanning electron microscopy and confocal laser scanning microscopy of in vitro-formed clots can give information on fibrin clot density and architecture.
- The radioiodine, is given to individuals, incorporated into a thrombus, and detected by scintigraphy.
Hyperfibrinogenemia
Levels of functionally normal fibrinogen increase in
History
Paul Morawitz in 1905 described fibrinogen.[37]
References
- ^ PMID 23852822.
- PMID 12808152.
- ^ S2CID 22077267.
- ^ S2CID 12038872.
- ^ PMID 21952526.
- S2CID 14997530.
- ^ S2CID 10878584.
- S2CID 12693693.
- PMID 27784620.
- ^ S2CID 27354717.
- ^ S2CID 9763486.
- ^ S2CID 24223328.
- ^ ISBN 9780128126165.
- PMID 13630928.
- PMID 5862426.
- S2CID 1575697.
- PMID 23621148.
- ^ PMID 27713652.
- S2CID 44911581.
- S2CID 10955092.
- PMID 19073821.
- PMID 28211264.
- S2CID 39645385.
- PMID 24679054.
- PMID 28550239.
- PMID 23519183.
- S2CID 10615690.
- S2CID 11733489.
- PMID 765622.
- S2CID 4959738.
- PMID 9771446.
- ]
- PMID 3277808.
- S2CID 23209838.
- PMID 8092895.
- PMID 28274749.
- PMID 16366177.
External links
- Jennifer McDowall/Interpro: Protein of the Month: Fibrinogen.
- Peter D'Eustachio/reactome: fibrinogen → fibrin monomer + 2 fibrinopeptide A + 2 fibrinopeptide B
- Khan Academy Medicine (on YouTube): Clotting 1 - How do we make blood clots?
- Overview of all the structural information available in the PDB for UniProt: P02671 (Fibrinogen alpha chain) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: P02675 (Fibrinogen beta chain) at the PDBe-KB.
- Overview of all the structural information available in the PDB for UniProt: P02679 (Fibrinogen gamma chain) at the PDBe-KB.